Literature DB >> 16101557

Neurodegenerative pathways in Parkinson's disease: therapeutic strategies.

S M Cardoso1, P I Moreira, P Agostinho, C Pereira, C R Oliveira.   

Abstract

Parkinson's disease (PD), considered one of the major neurological disorders, is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by the presence of intraneuronal cytoplasmic inclusions called Lewy bodies. The causes for degeneration of PD neurons remain unclear, however, recent findings contributed to clarify this issue. This review will discuss the current understanding of the mechanisms underlying Parkinson's disease pathogenesis, focusing on the current and potential therapeutic strategies for human treatment.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16101557     DOI： 10.2174/1568007054546072

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN： 1568-007X


  17 in total

Review 1.  Oxidative and inflammatory pathways in Parkinson's disease.

Authors:  Rebecca L Miller; Marilyn James-Kracke; Grace Y Sun; Albert Y Sun
Journal:  Neurochem Res       Date:  2008-03-25       Impact factor: 3.996

Review 2.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

3.  Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease.

Authors:  Laurie H Sanders; Jennifer McCoy; Xiaoping Hu; Pier G Mastroberardino; Bryan C Dickinson; Christopher J Chang; Charleen T Chu; Bennett Van Houten; J T Greenamyre
Journal:  Neurobiol Dis       Date:  2014-06-27       Impact factor: 5.996

4.  Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.

Authors:  Muhammet Ay; Jie Luo; Monica Langley; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neurochem       Date:  2017-05-09       Impact factor: 5.372

5.  Neuroprotective effect of curcuminoids against inflammation-mediated dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Rudra P Ojha; Manisha Rastogi; B Parimala Devi; Aruna Agrawal; G P Dubey
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-21       Impact factor: 4.147

6.  Microtubule depolymerization potentiates alpha-synuclein oligomerization.

Authors:  A Raquel Esteves; Daniela M Arduíno; Russell H Swerdlow; Catarina R Oliveira; Sandra M Cardoso
Journal:  Front Aging Neurosci       Date:  2010-01-04       Impact factor: 5.750

7.  Calpain-mediated MPP+ toxicity in mitochondrial DNA depleted cells.

Authors:  A Filipa Domingues; A Raquel F Esteves; Russell H Swerdlow; Catarina R Oliveira; Sandra M Cardoso
Journal:  Neurotox Res       Date:  2008-01       Impact factor: 3.911

8.  The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.

Authors:  D Jantas; A Roman; J Kuśmierczyk; E Lorenc-Koci; J Konieczny; T Lenda; W Lasoń
Journal:  Neurotox Res       Date:  2013-01-10       Impact factor: 3.911

Review 9.  Botanical phenolics and brain health.

Authors:  Albert Y Sun; Qun Wang; Agnes Simonyi; Grace Y Sun
Journal:  Neuromolecular Med       Date:  2008-11-01       Impact factor: 3.843

10.  Mitochondrial preconditioning: a potential neuroprotective strategy.

Authors:  Sónia C Correia; Cristina Carvalho; Susana Cardoso; Renato X Santos; Maria S Santos; Catarina R Oliveira; George Perry; Xiongwei Zhu; Mark A Smith; Paula I Moreira
Journal:  Front Aging Neurosci       Date:  2010-08-26       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.